Interview with Jean-François Mouney (Chairman and CEO of Genfit) at the ‘Liver Meeting 2015‘ congress for the American Association for the study of Liver disease (AASLD) on Friday in San Francisco (US).
Genfit is the European leader in NASH research (Non-alcoholic steatohepatitis), today making the news again at AASLD in San Francisco. The company, which is supported by the FDA through a fast-track designation, is shaking investors and storming competition thanks to promising news on its phase III trial design for Elafibranor.
First-in-class Elafibranor is addressing an unmet need related to the explosion of “dia-besity” (love it) worldwide, and as such, is being eyed by big pharmas like Gilead or AbbVie (both in the US), in need for a new power engine in liver disease after the Hepatitis C virus bubble.
In Februrary 2014, the US FDA granted Genfit Fast-track approval for Elafibranor in NASH patients during the phase IIb trial in 56 clinics across France,